July 25, 2017 | SOURCE: PR NEWSWIRE
Regen BioPharma, Inc. Research Demonstrates Ex-Vivo Immune Suppression With Novel NR2F6 ActivatorsNovel Activators Demonstrate Selective Inhibition of IL-17a and IL-2
July 12, 2017 |SOURCE: PR NEWSWIRE
Regen BioPharma, Inc. Researchers Discover New Dynamic Compound Which Modulates the NR2F6 CheckpointNew compound appears to be 10-fold more effective than previous compounds tested while showing no toxicity
May 16 , 2017| SOURCE: PR NEWSWIRE
Regen BioPharma, Inc. Sees Additional Positive Results on its Medicinal Chemistry Optimization for Modulating NR2F6 Checkpoint for Treating Cancer and Autoimmune Diseases
April 18, 2017 SOURCE: PR NEWSWIRE
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), in conjunction with its medicinal chemistry partner, ChemDiv, Inc., has identified three new series of compounds that activate NR2F6. These compounds are small molecules and were identified using Regen’s patented screening methodology and unique chemical libraries. ChemDiv, Inc. is a fully integrated Target-to-Clinic Contract Research Organization headquartered […]
April 12, 2017 SOURCE: PR NEWSWIRE
As previously reported, Regen BioPharma Inc. (OTCQB: RGBP), (OTCQB: RGBPP) has completed the first phase of its small molecule optimization program, which involved synthesizing more than 40 analogues of its initial lead compounds (RG-NA01, RG-NA02, RG-NI01 and RG-NI02). The compounds synthesized consist of activators (RG-NA01 and RG-NA02) and inhibitors (RG-NI01 and RG-NI02) of NR2F6 and […]
March 23, 2017 SOURCE: PR NEWSWIRE
Regen BioPharma Inc. (OTCQB: RGBP), (OTCQB: RGBPP) announced that its management team has agreed to collectively cancel 16,500,000 common shares and 15,000,000 Series A Preferred shares. Of these amounts, 7,500,000 common shares and 2,500,000 Series A Preferred shares were already cancelled in December 2016 with the remaining shares being submitted for cancellation on March 13, […]
March 23, 2017 SOURCE: PR NEWSWIRE
Regen BioPharma Inc. (OTCQB: RGBP), (OTCQB: RGBPP), has provided an update on the status of its medicinal chemistry program being conducted by ChemDiv Inc., for the optimization of its lead compounds, RG-NA01, RG-NA02, RG-NI01 and RG-NI02. These compounds are small molecules and consist of activators (RG-NA01 and RG-NA02) and inhibitors (RG-NI01 and RG-NI02) of NR2F6. […]
March 2, 2017 SOURCE: PR NEWSWIRE
Regen BioPharma Inc. (OTCQB: RGBP), (OTCQB: RGBPP) has granted CheckPoint Immunology Inc. (a wholly-owned subsidiary of the Company) an exclusive worldwide license to develop and commercialize Regen’s NR2F6 technology for human therapeutic use. The objective of the license grant is the separation of Regen’s small molecule technology from its other intellectual property in order to […]
December 16, 2016 SOURCE: PR NEWSWIRE
Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today identification of a series of compounds that have been identified by biochemical testing which interact with the Company’s newly identified immune checkpoint NR2F6. This is the first of a series of steps in developing small molecules which the Company plans to use as a basis […]
December 16, 2016 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma, Inc. Identifies Small Molecule Drug Candidates Targeting Its Proprietary Immune Checkpoint NR2F6